Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro. The company also recently announced a partnership with Walmart that will expand access to Zepbound ...
Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...
CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...
Eli Lilly's experimental weight-loss pill, orforglipron, has met key FDA criteria for an expedited review, boosting its ...
Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...
Eli Lilly and Company and Walmart Inc. today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect.
Eli Lilly & Co. has already produced billions of doses of its next-generation weight-loss pill, anticipating massive global ...
Pharmaceutical company Novo Nordisk is working on an Ozempic-style semaglutide tablet just for weight loss, and early results ...
The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback